v3.26.3
Collaborative, Licensing and Other Arrangements (Tables)
 9 Months Ended
Sep. 30, 2026
Research and Development [Abstract]  
Schedule of Net Product Sales
The following table summarizes total other revenue recognized for the three and nine months ended September 30, 2026 and 2025:
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
Other Revenue$$$$
Amgen royalty revenue25,744 12,169 62,864 26,721 
Novartis broad markets revenue6,869 4,115 17,088 10,957 
Other2,145 987 6,192 1,566 
Other Revenue34,758 17,271 86,144 39,244 
The table below presents the Company’s net product revenue for the three and nine months ended September 30, 2026 and 2025:
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
$$$$
Product revenue – gross2,436,062 1,770,689 6,535,151 4,828,593 
Less: rebates and sales returns(581,005)(375,676)(1,512,971)(1,022,974)
Product revenue – net1,855,057 1,395,013 5,022,180 3,805,619 
The following table disaggregates net product revenue by product for the three and nine months ended September 30, 2026 and 2025:
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
$$$$
BRUKINSA®
1,390,936 1,040,691 3,733,419 2,782,195 
TEVIMBRA®
243,282 190,623 678,038 555,311 
XGEVA®
105,482 84,243 299,901 235,984 
BLINCYTO®
38,869 30,476 109,441 79,969 
KYPROLIS®
13,900 18,369 46,018 57,513 
BAITUOWEI®
22,111 11,243 54,110 25,920 
POBEVCY®
10,717 10,499 32,477 35,486 
Other29,760 8,869 68,776 33,241 
Total product revenue – net1,855,057 1,395,013 5,022,180 3,805,619 
Schedule of Collaboration Agreements
Amounts recorded related to the Company’s portion of the co-development funding on the pipeline assets for the three and nine months ended September 30, 2026 and 2025 were as follows:
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
$$$$
BeOne’s portion of the development funding12,204 59,325 130,070 152,040 
Less: Amortization of research and development cost share liability6,182 29,275 64,345 74,844 
Research and development expense6,022 30,050 65,725 77,196 
The Company fulfilled its research and development cost share liability during the three months ended September 30, 2026. As of September 30, 2026 and December 31, 2025, the research and development cost share liability recorded in the Company’s balance sheet was as follows:
As of
September 30,December 31,
20262025
$$
Research and development cost share liability, current portion— 64,345 
Total research and development cost share liability— 64,345 
Schedule of Amounts and Classification of Reimbursement Expense
The total reimbursement paid under the commercial profit-sharing agreement for product sales is classified in the income statement for the three and nine months ended September 30, 2026 and 2025 as follows:
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
$$$$
Cost of sales - product5,859 9,962 29,772 26,989 
Research and development(1,332)(371)(2,657)(2,480)
Selling, general and administrative(32,870)(24,546)(86,395)(73,531)
Total(28,343)(14,955)(59,280)(49,022)
Schedule of Payments Due to Collaboration Partners
Upfront and milestone payments incurred under these arrangements for the three and nine months ended September 30, 2026 and 2025 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or term of the commercialization agreements.
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
Payments due to collaboration partnersClassification$$$$
Upfront paymentsResearch and development expense—191 20,518 691 
Development milestones incurredResearch and development expense757 — 4,070 — 
Regulatory and commercial milestone paymentsIntangible asset— — — 20,000 
Total757 191 24,588 20,691